310 related articles for article (PubMed ID: 31883552)
21. Designing Anticancer Peptides by Constructive Machine Learning.
Grisoni F; Neuhaus CS; Gabernet G; Müller AT; Hiss JA; Schneider G
ChemMedChem; 2018 Jul; 13(13):1300-1302. PubMed ID: 29679519
[TBL] [Abstract][Full Text] [Related]
22. Deep reinforcement learning for de novo drug design.
Popova M; Isayev O; Tropsha A
Sci Adv; 2018 Jul; 4(7):eaap7885. PubMed ID: 30050984
[TBL] [Abstract][Full Text] [Related]
23. Adversarial Threshold Neural Computer for Molecular de Novo Design.
Putin E; Asadulaev A; Vanhaelen Q; Ivanenkov Y; Aladinskaya AV; Aliper A; Zhavoronkov A
Mol Pharm; 2018 Oct; 15(10):4386-4397. PubMed ID: 29569445
[TBL] [Abstract][Full Text] [Related]
24. Recurrent Neural Network Model for Constructive Peptide Design.
Müller AT; Hiss JA; Schneider G
J Chem Inf Model; 2018 Feb; 58(2):472-479. PubMed ID: 29355319
[TBL] [Abstract][Full Text] [Related]
25. Automated De Novo Design in Medicinal Chemistry: Which Types of Chemistry Does a Generative Neural Network Learn?
Grebner C; Matter H; Plowright AT; Hessler G
J Med Chem; 2020 Aug; 63(16):8809-8823. PubMed ID: 32134646
[TBL] [Abstract][Full Text] [Related]
26. De Novo Design of Bioactive Small Molecules by Artificial Intelligence.
Merk D; Friedrich L; Grisoni F; Schneider G
Mol Inform; 2018 Jan; 37(1-2):. PubMed ID: 29319225
[TBL] [Abstract][Full Text] [Related]
27. De novo generation of hit-like molecules from gene expression signatures using artificial intelligence.
Méndez-Lucio O; Baillif B; Clevert DA; Rouquié D; Wichard J
Nat Commun; 2020 Jan; 11(1):10. PubMed ID: 31900408
[TBL] [Abstract][Full Text] [Related]
28. The power of deep learning to ligand-based novel drug discovery.
Baskin II
Expert Opin Drug Discov; 2020 Jul; 15(7):755-764. PubMed ID: 32228116
[TBL] [Abstract][Full Text] [Related]
29. Applications of Deep Learning in Molecule Generation and Molecular Property Prediction.
Walters WP; Barzilay R
Acc Chem Res; 2021 Jan; 54(2):263-270. PubMed ID: 33370107
[TBL] [Abstract][Full Text] [Related]
30. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities.
Gangwal A; Ansari A; Ahmad I; Azad AK; Kumarasamy V; Subramaniyan V; Wong LS
Front Pharmacol; 2024; 15():1331062. PubMed ID: 38384298
[TBL] [Abstract][Full Text] [Related]
31.
Zhang J; Chen H
J Chem Inf Model; 2022 Jul; 62(14):3291-3306. PubMed ID: 35793555
[TBL] [Abstract][Full Text] [Related]
32. De novo molecular design with deep molecular generative models for PPI inhibitors.
Wang J; Chu Y; Mao J; Jeon HN; Jin H; Zeb A; Jang Y; Cho KH; Song T; No KT
Brief Bioinform; 2022 Jul; 23(4):. PubMed ID: 35830870
[TBL] [Abstract][Full Text] [Related]
33. Shape-Based Generative Modeling for de Novo Drug Design.
Skalic M; Jiménez J; Sabbadin D; De Fabritiis G
J Chem Inf Model; 2019 Mar; 59(3):1205-1214. PubMed ID: 30762364
[TBL] [Abstract][Full Text] [Related]
34. De novo drug design as GPT language modeling: large chemistry models with supervised and reinforcement learning.
Ye G
J Comput Aided Mol Des; 2024 Apr; 38(1):20. PubMed ID: 38647700
[TBL] [Abstract][Full Text] [Related]
35. Trends in Deep Learning for Property-driven Drug Design.
Born J; Manica M
Curr Med Chem; 2021; 28(38):7862-7886. PubMed ID: 34325627
[TBL] [Abstract][Full Text] [Related]
36. Memory augmented recurrent neural networks for de-novo drug design.
Suresh N; Chinnakonda Ashok Kumar N; Subramanian S; Srinivasa G
PLoS One; 2022; 17(6):e0269461. PubMed ID: 35737661
[TBL] [Abstract][Full Text] [Related]
37. Artificial Intelligence, Machine Learning, and Deep Learning in Real-Life Drug Design Cases.
Muller C; Rabal O; Diaz Gonzalez C
Methods Mol Biol; 2022; 2390():383-407. PubMed ID: 34731478
[TBL] [Abstract][Full Text] [Related]
38. Transformer neural network for protein-specific de novo drug generation as a machine translation problem.
Grechishnikova D
Sci Rep; 2021 Jan; 11(1):321. PubMed ID: 33432013
[TBL] [Abstract][Full Text] [Related]
39. druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico.
Kadurin A; Nikolenko S; Khrabrov K; Aliper A; Zhavoronkov A
Mol Pharm; 2017 Sep; 14(9):3098-3104. PubMed ID: 28703000
[TBL] [Abstract][Full Text] [Related]
40. Guided structure-based ligand identification and design via artificial intelligence modeling.
Di Filippo JI; Cavasotto CN
Expert Opin Drug Discov; 2022 Jan; 17(1):71-78. PubMed ID: 34544293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
